Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.8/5
Alphamab Co Ltd (9966 HK)
Watchlist
Contact IR
117
Analysis
Health Care
•
China
Alphamab Oncology produces and sells drugs. The Company manufactures and sells tumor immunobiology macromolecular targeted drug and other products. Alphamab Oncology provides services worldwide.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
China Medical System
•
30 Jun 2025 00:55
Pre-IPO China Medical System (867 HK) - About the IPO in Singapore and Concerns on Valuation Outlook
Listing in SGX opens a new chapter and CMS is undergoing pipeline adjustments and strategic transformation. But as valuation logic changes, license...
Xinyao (Criss) Wang
Follow
314 Views
Share
bearish
•
Innovent Biologics Inc
•
29 Jun 2025 01:19
China Healthcare Weekly (Jun.29) - Biotech Valuation Bubble Is About to Burst, Innovent's Placement
The valuation bubble of innovative drug companies may burst soon, with some founders/shareholders already cashing out. Innovent's Placing Price of...
Xinyao (Criss) Wang
Follow
293 Views
Share
bullish
•
Nanjing Leads Biolabs
•
26 Jun 2025 00:55
Pre-IPO Nanjing Leads Biolabs (PHIP Updates) - Thoughts on the Valuation and the Outlook
LBL-024 won't boost performance due to small market,while LBL-007 face uncertain outlook.CD3 pipeline offer hope,but early investors' quit indicate...
Xinyao (Criss) Wang
Follow
254 Views
Share
bearish
•
Xuanzhu Biopharmaceutical
•
07 May 2025 00:55
Pre-IPO Xuanzhu Biopharmaceutical- Outdated Pipelines Are Difficult to Bring Good Investment Returns
Sihuan's acquisition of Combio aims to create a strong innovative drug business Xuanzhu, but concerns arise over its outdated pipeline,...
Xinyao (Criss) Wang
Follow
247 Views
Share
bullish
•
Duality Biotherapeutics
•
25 Mar 2025 00:55
Pre-IPO Duality Biotherapeutics (PHIP Updates) - Some Points Worth the Attention
DB-1303 face challenges in commercialization.The priority for DB-1311 is to verify the druggability. Duality’s pre-IPO valuation isn't...
Xinyao (Criss) Wang
Follow
407 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x